União Europeia - português - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vacinas - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

União Europeia - português - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacinas - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

União Europeia - português - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vacinas - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. o uso desta vacina deve ser de acordo com as recomendações oficiais.

União Europeia - português - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vacinas - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. o uso desta vacina deve ser de acordo com as recomendações oficiais.

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

bayer portugal, lda. - levonorgestrel - dispositivo de libertação intrauterino - 19.5 mg - levonorgestrel 19.5 mg - plastic iud with progestogen - n/a - duração do tratamento: longa duração

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

fundaÇÃo oswaldo cruz - vacina covid-19 (recombinante) - vacinas

União Europeia - português - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. o uso desta vacina deve ser de acordo com as recomendações oficiais. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. o uso desta vacina deve ser de acordo com as recomendações oficiais.

Portugal - português - DGAV (Direção Geral de Alimentação e Veterinária)

zoetis portugal, lda - moxidectina 19.5 mg ; praziquantel 121.7 mg - gel oral - associações de moxidectina - equinos (cavalos)

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

farmarin industria e comercio ltda - cloreto de potÁssio - reposicao hidroeletrolitica e alimentacao parenteral

Portugal - português - DGAV (Direção Geral de Alimentação e Veterinária)

moxidectina 19.5 mg ; praziquantel 121.7 mg - equinos